Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries
- 1 January 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 65 (1), e8-e16
- https://doi.org/10.1097/qai.0b013e3182a39979
Abstract
Objective: To describe the CD4 cell count at the start of combination antiretroviral therapy (cART) in low-income (LIC), lower middle-income (LMIC), upper middle-income (UMIC), and high-income (HIC) countries. Methods: Patients aged 16 years or older starting cART in a clinic participating in a multicohort collaboration spanning 6 continents (International epidemiological Databases to Evaluate AIDS and ART Cohort Collaboration) were eligible. Multilevel linear regression models were adjusted for age, gender, and calendar year; missing CD4 counts were imputed. Results: In total, 379,865 patients from 9 LIC, 4 LMIC, 4 UMIC, and 6 HIC were included. In LIC, the median CD4 cell count at cART initiation increased by 83% from 80 to 145 cells/μL between 2002 and 2009. Corresponding increases in LMIC, UMIC, and HIC were from 87 to 155 cells/μL (76% increase), 88 to 135 cells/μL (53%), and 209 to 274 cells/μL (31%). In 2009, compared with LIC, median counts were 13 cells/μL [95% confidence interval (CI): −56 to +30] lower in LMIC, 22 cells/μL (−62 to +18) lower in UMIC, and 112 cells/μL (+75 to +149) higher in HIC. They were 23 cells/μL (95% CI: +18 to +28 cells/μL) higher in women than men. Median counts were 88 cells/μL (95% CI: +35 to +141 cells/μL) higher in countries with an estimated national cART coverage >80%, compared with countries with <40% coverage. Conclusions: Median CD4 cell counts at the start of cART increased 2000–2009 but remained below 200 cells/μL in LIC and MIC and below 300 cells/μL in HIC. Earlier start of cART will require substantial efforts and resources globally.Keywords
This publication has 29 references indexed in Scilit:
- HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-MakingPLoS Medicine, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyThe New England Journal of Medicine, 2011
- Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countriesAIDS, 2011
- Late Presentation for Human Immunodeficiency Virus Care in the United States and CanadaClinical Infectious Diseases, 2010
- Effect of Early versus Deferred Antiretroviral Therapy for HIV on SurvivalThe New England Journal of Medicine, 2009
- Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesThe Lancet, 2009
- Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studiesAIDS, 2008
- Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART StudyThe Journal of Infectious Diseases, 2008
- When should antiretroviral therapy for HIV be started?BMJ, 2007
- Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)International Journal of Epidemiology, 2007